申请人:JOHN WYETH & BROTHER LIMITED
公开号:EP1123926A1
公开(公告)日:2001-08-16
Compounds of formula
where A is an alkylene chain of 1 or 2 carbon atoms optionally substituted by one or more lower alkyl groups, R is hydrogen or lower alkyl, R1 is a mono or bicyclic aryl or a heteroaryl radical, R2 is an aryl radical, a heteroaryl radical, or an aryl-or heteroaryl-lower alkyl radical, R3 is hydrogen, lower alkyl or aryl and R4 is hydrogen, lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, or aryl(lower)alkyl or R3 and R4 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom and the dotted line represents a single or double bond, the hydrogen atoms shown in brackets being present when the dotted line represents a single bond and their pharmaceutically acceptable acid addition salts are 5-HT1A binding agents which may be used, for example, for the treatment of CNS disorders such as anxiety.
式中A为1或2个碳原子的烷基链,可以选择性地被一个或多个较低的烷基基团取代,R为氢或较低的烷基,R1为单环或双环芳基或杂芳基基团,R2为芳基基团、杂芳基基团或芳基或杂芳基的较低烷基基团,R3为氢、较低的烷基或芳基,R4为氢、较低的烷基、环烷基、环烷基(较低)烷基、芳基或芳基(较低)烷基,或R3和R4与它们共同连接的氮原子一起代表一个饱和杂环环,该环可能含有进一步的杂原子,虚线代表一个单键或双键,括号中显示的氢原子表示当虚线代表单键时存在,它们的药用可接受的酸盐是5-HT1A结合剂,例如可用于治疗焦虑等中枢神经系统疾病。